- Home
- MRM vs JAGX Comparison
MRM vs JAGX Comparison
Compare MRM & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- JAGX
- Stock Information
- Founded
- MRM 2000
- JAGX 2013
- Country
- MRM Japan
- JAGX United States
- Employees
- MRM N/A
- JAGX N/A
- Industry
- MRM Other Consumer Services
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- JAGX Health Care
- Exchange
- MRM Nasdaq
- JAGX Nasdaq
- Market Cap
- MRM 12.2M
- JAGX 10.8M
- IPO Year
- MRM 2020
- JAGX N/A
- Fundamental
- Price
- MRM $3.89
- JAGX $1.11
- Analyst Decision
- MRM
- JAGX
- Analyst Count
- MRM 0
- JAGX 0
- Target Price
- MRM N/A
- JAGX N/A
- AVG Volume (30 Days)
- MRM 2.1M
- JAGX 263.4K
- Earning Date
- MRM 01-01-0001
- JAGX 08-13-2024
- Dividend Yield
- MRM N/A
- JAGX N/A
- EPS Growth
- MRM N/A
- JAGX N/A
- EPS
- MRM 0.16
- JAGX N/A
- Revenue
- MRM $48,438,179.00
- JAGX $10,185,000.00
- Revenue This Year
- MRM N/A
- JAGX $32.33
- Revenue Next Year
- MRM N/A
- JAGX $43.63
- P/E Ratio
- MRM $25.43
- JAGX N/A
- Revenue Growth
- MRM N/A
- JAGX N/A
- 52 Week Low
- MRM $2.27
- JAGX $0.95
- 52 Week High
- MRM $8.39
- JAGX $31.74
- Technical
- Relative Strength Index (RSI)
- MRM 50.99
- JAGX 33.13
- Support Level
- MRM $3.50
- JAGX $1.09
- Resistance Level
- MRM $4.14
- JAGX $1.16
- Average True Range (ATR)
- MRM 0.70
- JAGX 0.04
- MACD
- MRM -0.06
- JAGX 0.07
- Stochastic Oscillator
- MRM 10.84
- JAGX 34.55
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.